Hepatic Resection for Breast Cancer Liver Metastases
Jorge P Grondona*, Adrián Hannois, Ricardo A Bracco, Pedro J Angiolini, Ignacio G Merlo, Roberto Acevedo, Diego Enrico and Jeannette Burton
Hepato-Pancreato-Biliary Unit of the Oncological Surgery Centre of UNACIR HPB (Associated Units in Hepato-Pancreato-Biliary Surgery) at the Sanatorio San Lucas of San Isidro, Provincia de Buenos Aires, Argentina
- *Corresponding Author:
- Jorge P Grondona
Head of the Hepato-Pancreato-Biliary Unit
and Director of the Fellowship in HPB Surgery
Hepato-Pancreato-Biliary Unit of the Oncological
Surgery Centre of UNACIR HPB (Associated Units in
Hepato-Pancreato-Biliary Surgery) at the Sanatorio
San Lucas of San Isidro, Provincia de Buenos
E-mail: [email protected]
Received date: March 31, 2016; Accepted date: April 27, 2016; Published date: May 2, 2016
Citation: Grondona JP, Hannois A, Bracco RA, Angiolini PJ, Merlo IG, et al. (2016) Hepatic Resection for Breast Cancer Liver Metastases . J Cancer Clin Trials 1:110. doi:10.4172/jcct.1000110
Copyright: © 2016 Grondona JP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: To review the experience of a single Oncological Surgery Centre regarding the benefit of hepatic resection in breast cancer liver metastases (BCLM) patients with unique focus in overall survival rate, and compare these results with matched individuals of other group of BCLM patients treated only with chemotherapy and/or hormonal regimens.
Patients and methods: Between July 2007 and July 2015, a total of 260 female patients with BCLM were entered prospectively into a database of our Surgical Oncological Centre, and were all evaluated by their Multidisciplinary Team. Two groups of patients were enlisted: 1) Surgical Group (SG) enrolled by 36 patients which were suitable to receive a hepatic resection; 2) Non-Surgical Group (NSG) integrated by 20 that could receive medical treatment alone. Patients with 5 or more liver metastases and/or uncontrolled extra hepatic metastatic disease were excluded in this series. However, patients with slight extra hepatic disease that were treated and were deemed stable or certainly improving were included.
Results: Concerning with SG there was no postoperative mortality and perioperative complications occurred in 11 out of 36 patients (30.5%). Histopathological examination confirmed in all cases free tumor margin (R0). Followup of 100% for all patients. Median overall survival was 55.2 months in the SG vs 23.6 months in the NSG. Actuarial 1-year, 3-year and 5-year survival rates were 100%, 84% and 61.6% respectively in the SG vs 65%, 28% and 0% respectively in the NSG (p=0.000).
Conclusions: Surgical treatment is only indicated in a select group of patients and can improve long-term outcomes. In this study, significantly better survival rates were observed in the surgical group that encourage continuing in this line of multimodal treatment. Surgical therapy can act as an effective adjuvant treatment to systemic therapies, providing selected patients a survival benefit as well as the hope for cure.